Axonics Sacral Neuromodulation System
BOSTON SCIENTIFIC CORPORATION · Decision date Dec 19, 2025
What did the FDA decide?
FDA records P180046/S101 as a supplement to PMA P180046, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 19, 2025.
FDA approval order statement
approval for using updated operating parameters on the sterile pouch sealers, as well as qualifying a new duplicate pouch sealer with the updated parameters
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Dec 19, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P180046/S101
- Regulatory pathway
- PMA supplement
- Applicant
- BOSTON SCIENTIFIC CORPORATION
- Product code
- EZW
- Decision code
- OK30
- Decision date
- Dec 19, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, electrical, implantable, for incontinence.
- Applicant
- Boston Scientific Corporation
- Product code
- EZW
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P180046/S101 received
Application receipt date recorded by FDA.
P180046/S101 · FDA decision
30-Day Notice
P180046/S102 · Related supplement
Axonics Sacral Neuromodulation System
P180046/S103 · Related supplement
Axonics Sacral Neuromodulation System
P180046/S104 · Related supplement
Axonics Sacral Neuromodulation System
P180046/S106 · Related supplement
Axonics Sacral Neuromodulation System
P180046/S108 · Related supplement
Axonics Sacral Neuromodulation System
P180046/S105 · Related supplement
Axonics Sacral Neuromodulation System
P180046/S107 · Related supplement
Axonics Sacral Neuromodulation System
P180046/S099 · Related supplement
Axonics Sacral Neuromodulation System
P180046/S100 · Related supplement
Axonics Sacral Neuromodulation System
P180046/S109 · Related supplement
Axonics Sacral Neuromodulation System
P180046/S111 · Related supplement
Axonics Sacral Neuromodulation System
P180046/S112 · Related supplement
Axonics SNM System
P180046/S110 · Related supplement
Axonics Sacral Neuromodulation System
P180046/S113 · Related supplement
Axonics Sacral Neuromodulation System
Timeline entries are records held by MedtechLedger for P180046. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180046
Explore the linked device profile
Other records with product code EZW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 9, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 6, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Sep 14, 2026 | FDA | |
Neuspera Sacral Neuromodulation (SNM) SystemP240031/S005 | Neuspera Medical, Inc. | PMA supplement | Aug 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corporation
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 100 Boston Scientfic Way, Marlborough, MA, 01752
Sources and methodology
- Original FDA record: P180046/S101
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



